Genetic mouse studies suggest that the NF-NB pathway regulator NEMO (also known as IKKJ) controls chronic inflammation and carcinogenesis in the liver.
Abstract
Genetic mouse studies suggest that the NF-NB pathway regulator NEMO (also known as IKKJ) controls chronic inflammation and carcinogenesis in the liver.
However the molecular mechanisms explaining the function of NEMO are not well defined. Here we report that overexpression of the cell cycle regulator p21 is a critical feature of liver inflammation and carcinogenesis caused by the loss of NEMO.
NEMO
Δhepa mice develop chronic hepatitis characterized by increased hepatocyte apoptosis and proliferation that causes the development of fibrosis and hepatocellular carcinoma, similar to the situation in human liver disease. Having identified p21 overexpression in this model, we evaluated its role in disease progression and LPS-mediated liver injury in double mutant NEMO Δhepa /p21 -/-mice.
Eight week-old NEMO Δhepa /p21 -/-animals displayed accelerated liver damage that was not associated with alterations in cell cycle progression or the inflammatory response. However, livers from NEMO Δhepa /p21 -/-mice displayed more severe DNA damage that was further characterized by LPS administration correlating with higher lethality of the animals. This phenotype was attenuated by genetic ablation of the TNF receptor TNF-R1 in NEMO Δhepa /p21 -/-mice, demonstrating that DNA damage is induced via TNF. One year old NEMO Δhepa /p21 -/-mice displayed greater numbers of hepatocellular carcinoma and severe cholestasis compared to NEMO Δhepa animals.
Therefore, p21 overexpression in NEMO Δhepa animals protects against DNA damage, acceleration of hepatocarcinogenesis and cholestasis. Taken together, our findings illustrate how loss of NEMO promotes chronic liver inflammation and carcinogenesis, and they identify a novel protective role for p21 against the generation of DNA damage.
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and represents the third leading cause of cancer-related mortality (1) . HCC develops when the balance between cell proliferation and cell death is disrupted, and the subsequent aberrant proliferation leads to tumor growth. Cell proliferation is controlled by protein kinase complexes consisting of cyclins and cyclin-dependent kinases (Cdks), which regulate distinct phases of the cell cycle.
p21 is involved in numerous growth-inhibitory pathways as shown in cell culture systems and in vivo (2) . For example embryonic fibroblasts lacking p21 expression are significantly impaired in their ability to arrest in G1 phase in response to DNA damage (3) , and in vivo experiments with p21 knockout mice (p21 -/-) revealed earlier hepatocyte DNA synthesis, cyclin/CDK kinase activation and S phase gene expression compared to wild-type mice in the partial hepatectomy (PH) model (4) . In contrast, after PH mice with hepatic p21 overexpression displayed impaired hepatocyte proliferation (5) .
p21 has been considered as a tumor suppressor because p21 -/-mice display spontaneous tumor formation after 16 months and additionally these mice are more sensitive to chemically induced carcinogenesis (6)(7).
However, deletion of p21 does not necessarily promote tumor growth and a potential function as an oncogene has also been described. These assumptions are based on human studies as it has been shown that p21 is upregulated during inflammation and fibrosis in chronic liver diseases, and high p21 expression is linked to hepatocarcinogenesis in cirrhotic patients (8) (9) . An oncogenic function for p21
has also been proposed in animal models. Mice deficient for p53 spontaneously develop multiple tumors while additional deletion of p21 in p53-deficient mice increases the survival of these mice from 6 to 9 months and for instance leads to a significant reduction of thymic lymphomas (10) .
From these data at present the role of p21 in tumorigenesis is not clearly defined. In our present study we thus used the NEMO 'hepa model to investigate the role of p21 during inflammation driven liver carcinogenesis. The NEMO Δhepa model is of specific interest as loss of NEMO immunoreactivity in liver cells is also found in a substantial proportion of human HCCs and in the mouse model it resembles stage dependent evolution of chronic liver disease as also found in humans leading to fibrosis progression and the occurrence of HCC (11)(12)(1).
Our group showed that deletion of NEMO in hepatocytes triggers increased p21 expression (13) . In the present study we aimed to investigate whether p21 overexpression in NEMO 'hepa livers has a tumor suppressive or oncogenic function.
We demonstrate here that p21 overexpression is protective in this model, as hepatocarcinogenesis and cholestasis is significantly enhanced upon deletion of p21 in NEMO 'hepa mice. Therefore our study defines p21 as a tumor suppressor in this inflammation triggered model for liver carcinogenesis. 
Material and Methods

Animal approach.
Mice were housed and treated in accordance with the guidelines of the National Academy of Sciences (NIH publication 86-23 revised 1985) and breed in the animal facility of the University Hospital RWTH Aachen. Animal studies were approved by the regional authorities for nature, environment and consumer protection of the state North Rhine-Westphalia (LANUV, Germany).
NEMO
'hepa and p21 -/-mice were generated as previously described (12) (17) . Genes were filtered on an intensity level of at least 20 in at least two samples and an interquartile range > 0.2 (log2 scale). Intensity basedmoderated t-statistics were used to calculate significant differences (18) . All data were analyzed using an in-house developed system (19) . Data is available in the Gene Expression Omnibus (GEO accession number: GSE61100).
Statistical Analysis.
Data are presented as mean ± standard deviation of the mean. Statistical significance was determined by Students t test. 
Results
P21 overexpression protects NEMO
' 'hepa mice from severe liver injury.
Deletion of NEMO in hepatocytes triggers apoptosis and compensatory proliferation in the liver. Unexpectedly, the Cdk inhibitor p21, known to inhibit cell cycle proliferation, is overexpressed under these conditions (Fig. 1A) . In order to characterise the role of p21 for progression of chronic liver injury, we generated NEMO 'hepa /p21 -/-double knockout mice ( Fig. 1A and supplementary Fig. 1A ). Fig. 2A-E) . Overexpression of CcnA2 and E2F1 was confirmed by Western blot analysis, which also showed a downregulation of the mitogen inducible Cyclin D (CcnD) in p21-deleted NEMO 'hepa livers (Fig. 1C) .
Unpredicted, elevation of the S-phase marker CcnA2 was not accompanied by an increase in hepatocyte proliferation, as evidenced by quantification of BrdU incorporation ( Fig. 1D ) and Ki67 staining (supplementary Fig. 2F Fig. 2G ).
As deletion of p21 had no impact on DNA replication, we examined potential mechanisms, which might explain the lack of an increase in DNA replication in NEMO 'hepa /p21 -/-livers. We thus investigated the protein expression of the Cdk inhibitors p27 and p18 by Western blot analysis. NEMO 'hepa /p21 -/-livers revealed slightly increased p27 phosphorylation and additionally p18 was upregulated ( We previously demonstrated that NEMO 'hepa livers display mild DNA double strand breakage (13) . Based on the shown differences in NEMO 'hepa /p21 -/-livers we next focussed more specifically on the relevance of p21 deletion for DNA damage in these mice. Loss of p21 expression strongly and significantly enhanced DNA damage in NEMO 'hepa /p21 -/-compared to NEMO 'hepa livers as evidenced by pH2AX staining (Fig. 2B ). To better characterise these findings, we performed array analysis to detect changes in the expression of genes involved in DNA damage. Interestingly, we found an upregulation of the DNA checkpoint kinase Chk2 and further genes involved in DNA repair such as the transcription factor FoxM1 and the recombinase Rad51 in Inflammation is ameliorated in the absence of p21 in the NEMO ' 'hepa liver.
The inflammatory response leading to chronic hepatitis is important to drive liver disease progression in NEMO 'hepa mice. CD45 immunohistochemistry pointed to a strong inflammatory response in NEMO 'hepa livers. Unexpectedly, p21 deletion reduced CD45 staining in NEMO 'hepa /p21 -/-livers (Fig. 3A) . This finding was further confirmed by Q-RTPCR (supplementary Fig. 3 ). The infiltrating cells were also positive for the macrophage marker F4/80 (Fig. 3B) . Additionally, these findings were associated with a reduced expression of TNF and upregulation of its negative regulator TIMP3 (Fig. 3C,D) . Together these findings suggest that the inflammatory response is reduced in NEMO 'hepa /p21 -/-livers arguing that the changes in DNA damage might be relevant to explain the phenotype of NEMO 'hepa /p21 -/-livers.
P21 deletion increases the sensitivity towards DNA damage.
Lipopolysaccharide (LPS) has been shown to induce DNA strand breakage (20) . Therefore we tested if loss of p21 expression increases sensitivity against LPSdriven DNA damage. In wt animals (NEMO f/f ) minor DNA double strand breakage, as detected by pH2AX staining, was observed after LPS stimulation (Fig. 4A) . In p21
livers the amount of pH2AX-positive cells was significantly increased, indicating that p21 is involved in mediating protection against DNA damage. In NEMO 'hepa livers LPS triggered strong DNA damage, which was significantly enhanced in NEMO 'hepa /p21 -/-livers. These findings further support our idea that p21 counter-acts DNA damage in NEMO-deficient hepatocytes.
Next, we tested the impact of LPS stimulation on liver injury. In agreement with our previous studies, NEMO 'hepa mice showed a severe increase in ALT and AST levels after LPS treatment, which was nearly doubled in NEMO 'hepa /p21 -/-animals ( Fig 4B, supplementary Fig. 5A ). This observation was also reflected in liver histology as determined by H&E staining. Here NEMO 'hepa /p21 -/-animals showed severe haemorrhages within the liver tissue, which was not evident in NEMO 'hepa livers and the respective controls (Fig 4C) . To further characterise the mode of cell death, we performed TUNEL-staining and found that the number of TUNEL-positive areas was significantly highest in NEMO 'hepa /p21 -/-livers suggesting that the increase in DNA damage and higher liver injury was associated with increased apoptosis (Fig 4D) . Fig. 4A ).
Furthermore we analyzed IL-6 expression levels by Q-RTPCR and found that NEMO 'hepa and NEMO 'hepa /p21 -/-livers also showed comparable IL-6 levels (supplementary Figure 4B) . As IL-1ß and IL-6 regulation are not different between both mouse strains after LPS stimulation, these results indicate that the higher sensitivity of NEMO 'hepa /p21 -/-hepatocytes also explain the higher mortality of these animals.
The oxidative stress response in the liver of LPS treated mice was measured by CM-H 2 DCFDA staining to detect reactive oxygen species (ROS) (supplementary Therefore we conclude that oxidative stress does not account for higher DNA damage in NEMO 'hepa p21 -/-livers.
Recently we have described that TNF-R1 deletion in NEMO 'hepa livers rescues hepatocyte injury and apoptosis (14 Fig. 5B ). H&E staining demonstrated that acute liver haemorrhage was completely prevented in triple knockout mice (supplementary Fig.   5C ). Additionally, DNA double strand breakage was significantly reduced after TNF-R1 deletion in NEMO 'hepa /p21 -/-livers (supplementary Fig. 5D ). Importantly, 57% of NEMO 'hepa /p21 -/-mice did not survive the first 7 hours after LPS stimulation, while none of the WT mice and only 14% of the NEMO 'hepa animals died during this observation period. Interestingly, deletion of TNF-R1 was highly beneficial as all
-/-/TNF-R1 -/-animals survived the challenge (supplementary Fig. 5E ).
This suggests that the LPS-hypersensitivity due to lack of p21 is mediated via TNFdependent signaling.
NEMO
' 'hepa /p21 -/-livers show increased cholestasis associated with changes in biliary architecture.
Macroscopic analysis of livers from 52 week-old NEMO
'hepa /p21 -/-animals revealed an overall yellowish appearance (Fig. 5A) . As a result we studied markers of cholestasis and found that alkaline phosphatase (AP) (Fig. 5B ), total and direct bilirubin levels (supplementary Fig. 6A 5F ).
p21 deletion promotes hepatocarcinogenesis.
The long term consequences of increased injury in NEMO 'hepa /p21 -/-livers were assessed in 52 week-old animals. Macroscopically NEMO 'hepa /p21 -/-livers showed more tumor nodules compared to NEMO 'hepa mice (Fig 6A) . The tumors displayed broadening of liver cell cords and loss of the reticulin network. In order to microscopically classify the observed nodules we performed stainings with established HCC markers like Golgi protein-73 (GP73) and glutamine synthetase (GS) (Fig. 6B ) demonstrating that tumors in both strains classified as HCCs.
Liver/body weight ratio was significantly enhanced in NEMO 'hepa /p21 -/-livers ( Fig. 6C) as well as liver injury markers like ALT and AST (Fig. 6D, supplementary Fig. 7 ).
Quantification of hepatocarcinogenesis revealed a significantly higher number of tumors per liver in NEMO 'hepa /p21 -/-compared to NEMO 'hepa mice (Fig. 6E) , while the average size of these tumors was similar between the groups (Fig. 6F ).
Earlier tumor onset in 26 week old double knockout mice. (Fig. 7A) . These changes were associated with a higher liver/body weight ratio (Fig. 7B) . Additionally, at this time point more Ki67 positive cells were found in the liver of NEMO 'hepa /p21 -/-animals suggesting higher proliferation in 26 week-old livers (Fig. 7C) .
In order to better characterize the 26 week tumors, we performed staining for CK19, Gp73 and GS. Our result shows that in NEMO 'hepa as well as in 
Discussion
The role of p21 for tumorigenesis is not fully understood. Convincing studies demonstrated that p21 can act as an oncogene as well as a tumor suppressor. In the present study we aimed to investigate the relevance of p21 for hepatocarcinogenesis in the NEMO 'hepa mouse model. This model is of clinical interest as these animals develop a cascade of events as also found in humans, which leads from chronic hepatitis to liver cirrhosis and growth of hepatocellular carcinomas (HCC).
Interestingly, we found in human HCC that NEMO is downregulated thus indicating that results found in NEMO 'hepa livers might have a direct relevance for human liver diseases (1).
In former studies we found in NEMO 'hepa livers an overexpression of the cell cycle inhibitor p21 (13) . To study its relevance for disease progression, we generated NEMO Δhepa /p21 -/-double knockout mice and examined the relevance of p21 deletion for disease progression and its sensitivity towards LPS-induced liver injury.
Because p21 is a cell cycle inhibitor we first investigated the impact on cell proliferation in NEMO Δhepa /p21 -/-livers. Interestingly in 8 week-old animals p21 deletion had no influence on the proliferation of hepatocytes. This was an unexpected result since p21 binds to CcnE/cdk2 and CcnA/cdk2 complexes thereby preventing progression from G 1 -to S-phase. At present we propose that loss of p21 expression is compensated by the increased activity of other cell cycle inhibitors such as p-p27 and p18, which is supported by our present data. Hence, TIMP3 is an important negative TNF regulator (22) . As a consequence of reduced cytokine production the mitogenic stimulation of CcnD was decreased in 8 week-old NEMO 'hepa /p21 -/-livers.
Despite a reduced inflammatory response the loss of p21 expression triggered increased liver injury in NEMO 'hepa mice, which was reflected by elevated serum transaminases (AST). Further analysis revealed that increased liver injury in the double knockout mice is mediated through enhanced DNA damage. As a consequence of higher DNA damage the expression of important mediators for DNA repair (BRCA1, RAD51 and FoxM1) were enhanced in NEMO 'hepa /p21 -/-livers.
However, several recent studies suggested that overexpression of DNA repair proteins is associated with a disadvantage for the treatment of breast cancer, glioblastoma multiforme and human soft tissue sarcoma cells, as they mediate resistance to chemotherapy. This has been nicely shown for FoxM1 and RAD51 mediating resistance against chemotherapeutics like Doxorubicin (23)(24)(25)(26).
Thus these findings indicated that loss of p21 in NEMO 'hepa liver may lead to more aggressive disease progression and likely a higher rate of HCCs.
A responsible mechanism for exacerbation of DNA damage in p21-deficient NEMO 'hepa mice could be the elevated expression of CcnA2 and CcnE2 which did not cause enhanced hepatocyte proliferation in 8 week-old animals. Recent publications showed that ectopic overexpression of CcnA or CcnE in mouse embryonic fibroblast (MEFs) lead to an increase in DNA double strand breakage (27) .
The observed down-regulation of CcnD, a protein also known to be involved in DNArepair mechanisms (28) , might additionally contribute to enhanced DNA damage in NEMO 'hepa /p21 -/-livers (28). 
Hepatocyte-specific deletion of NEMO inhibits activation of NF-NB and causes substantial apoptosis in the liver after LPS-injection (11) . p21 has an additional function in the suppression of autoimmunity and in the inhibition of apoptosis (29)(30). We therefore investigated if p21 overexpression in NEMO 'hepa livers can provide protection after challenging the animals with LPS.
Our LPS experiments strongly suggest that p21 has a yet unknown function in protecting from DNA damage. As LPS-dependent cytotoxicity is mainly mediated through TNF, we tested if the p21-dependent effect on DNA damage is also related to this pathway and deleted TNF-R1 in NEMO 'hepa /p21 -/-mice. The triple knockout
) show a massive reduction in DNA damage and cell death. Additionally, AST serum values and liver histology was significantly improved. Finally, all triple knockout mice survived the LPS challenge suggesting that the LPS-dependent effect on DNA damage in p21 deleted animals is mediated via TNF.
As p21 deletion triggered higher DNA damage resulting in higher liver injury we examined the relevance for spontaneous hepatocarcinogenesis in aging mice.
Here, the protective role of p21 was already visible in NEMO 'hepa mice at the age of 26 weeks. Double knockout mice at this age had already a higher liver weight/body weight ratio and more frequently showed small tumors. At this age p21 deletion also resulted in enhanced hepatocyte proliferation as evidenced and quantified by Ki67 staining. Finally, loss of p21 overexpression caused exacerbation of hepatocarcinogenesis which resulted in a significantly increased number of HCCs in 52 week-old animals. Interestingly, only the number of HCC nodules was increased
and not the size of the tumors itself suggesting that the loss of p21 has more impact on tumor initiation than on tumor progression. 
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